Developer docs
API playgroundTry for free, no card

Search company profiles

Rezolute

Full company profile

uuid0002w8v

Namestring
Rezolute
Legal namestring
Rezolute, Inc.
Websiteurl
rezolutebio.com
Company typeenum
Public
Founded yearint
2017
Descriptiontext

Rezolute (NASDAQ: RZLT) is a clinical-stage biopharmaceutical company developing ersodetug (RZ358), a fully human monoclonal antibody that binds allosterically to the insulin receptor in liver, fat, and muscle tissue to modulate insulin signaling. The company targets two forms of hyperinsulinism (HI): congenital hyperinsulinism (CHI), a rare pediatric genetic disorder affecting approximately 1 in 22,000 births worldwide, and tumor hyperinsulinism driven by insulinomas or non-islet cell tumors in adults. Two Phase 3 registrational trials are in progress: the sunRIZE study in CHI and the upLIFT study in tumor HI. The company holds multiple regulatory designations including FDA Orphan Drug, FDA Pediatric Rare Disease, EU Orphan Drug, EMA PRIME, UK ILAP Innovation Passport, and is engaging with FDA under Breakthrough Therapy framework following the December 2025 sunRIZE readout. Ersodetug's mechanism of action — acting downstream of the pancreas — provides potential pan-etiology efficacy across genetic, acquired, and tumor-driven forms of HI.

Rezolute's revenue model is contingent pharmaceutical drug sales targeting rare disease populations once regulatory approval is secured; the company is currently pre-revenue. Commercial infrastructure buildout is underway through a Chief Commercial Officer with prior ultra-rare disease launch experience (Crysvita at Ultragenyx), a Chief Regulatory Officer with 13 years at Genzyme, and a dedicated VP of Medical & Patient Affairs. Go-to-market positioning targets specialized endocrinology treatment centers and key opinion leaders, supplemented by an Expanded Access Program and The Rezolution patient community platform in collaboration with international advocacy organizations including Congenital Hyperinsulinism International.

The business carries a single-asset, binary-clinical-event risk profile. The December 2025 sunRIZE Phase 3 primary endpoint failure caused an 85–90% stock decline; the FDA subsequently declined to require a new controlled trial and encouraged broader data submission. The June 2026 positive upLIFT interim data and Guggenheim analyst modeling of approximately $850M in peak U.S. sales support a partial recovery narrative. Capital base stood at $120.3M cash and investments as of March 31, 2026, against a market capitalization of approximately $418M in June 2026, with the company's headquarters in Redwood City, California and additional offices in Bend, Oregon and New York.

Short descriptiontext

Rezolute is a clinical-stage biopharmaceutical company developing ersodetug, a fully human monoclonal antibody for hyperinsulinism, targeting rare pediatric congenital and adult tumor patient populations suffering severe hypoglycemia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersRedwood City, United States
HQ citystring
Redwood City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease therapeutics, monoclonal antibody therapy, hyperinsulinism treatment, biopharmaceutical development, metabolic disease drugs
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Rare Disease Biopharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Drug Sales
TypeOne Time License
Description

Pre-revenue biopharmaceutical company developing er sodetug for treatment of congenital and tumor hyperinsulinism. Once approved, the company expects to generate revenue through pharmaceutical product sales targeting rare disease populations.

rezolutebio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1The Rezolution
Description

Patient advocacy and community initiative providing updates on therapy innovations, community events, and educational support for the hyperinsulinism community.

rezolutebio.com
Core offering1 text field

Rezolute is developing ersodetug (RZ358), a fully human monoclonal antibody designed to treat all forms of hyperinsulinism (HI) by binding allosterically to the insulin receptor at liver, fat and muscle tissues to modulate insulin signaling and maintain glucose in a normalized range. The drug is being evaluated in two Phase 3 registrational trials: sunRIZE for congenital HI and upLIFT for tumor HI. The company also operates an Expanded Access Program (compassionate use) for patients with severe hypoglycemia and no alternative treatments.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 75% of tumor HI patients achieved complete discontinuation of IV dextrose/TPN support in Expanded Access Program
+2 more records
Product overview1 text field

Rezolute is a biopharmaceutical company developing novel therapies for rare diseases, specifically focused on hypoglycemia caused by hyperinsulinism. The company's lead product is ersodetug (RZ358), a fully human monoclonal antibody that acts downstream from the pancreas to modulate insulin receptor signaling and maintain glucose levels. The development pipeline includes two Phase 3 registrational programs: the sunRIZE study for congenital hyperinsulinism and the upLIFT study for tumor hyperinsulinism. The company also operates an Expanded Access Program for compassionate use and supports patient communities through The Rezolution initiative. Currently, no product has received regulatory approval.

Product and service1 record
1Ersodetug (RZ358)
CategoryLead Therapeutic Candidate
Description

Ersodetug (RZ358) is Rezolute's lead investigational product, a fully human monoclonal antibody designed to treat all forms of hyperinsulinism (HI). It binds allosterically to the insulin receptor at target tissues in the liver, fat and muscle to modulate the binding and signaling effects of insulin to help maintain glucose values in a normalized range, acting downstream of the pancreas for potential universal effectiveness. Currently in two Phase 3 registrational trials (sunRIZE for congenital HI and upLIFT for tumor HI).

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierMinorTypeOthers
Description

Former Rezolute executive Keith Vendola joined NervGen Pharma as CFO, indicating personnel exchange between the companies but no active business partnership.

2Congenital Hyperinsulinism International (CHI)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Patient advocacy organization founded by caregivers and patients impacted by HI. Rezolute's VP Medical & Patient Affairs previously served 7 years as Board President of CHI, helping launch the HI Global Registry and CHI Centers of Excellence program.

rezolutebio.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Rezolute collaborates with multiple patient advocacy organizations including hiperinsulinismo congenito, hyperinsulinismus.de (Germany), Children's HI Charity (UK), Insulinoma.co.uk, and Neuroendocrine Cancer Foundation. These organizations provide education, research, clinical care, and support to affected communities.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biopharma developing therapies for rare endocrine diseases including acromegaly and congenital hyperinsulinism (paltusotine). Similar rare metabolic focus, comparable development stage, and overlapping target patient populations make Crinetics the most direct comparable.

TypeDirect peer
Description

Rare disease biopharma focused on Prader-Willi syndrome and related metabolic disorders. Similar clinical-stage profile, ultra-rare disease commercial model, and comparable market capitalization make Soleno a closely matched peer.

TypeBroad incumbent
Description

Established commercial-stage rare disease company with multiple ultra-rare product launches including Crysvita for X-linked hypophosphatemia. Comparable ultra-rare disease commercial infrastructure and shared leadership bench (multiple ex-Ultragenyx executives at Rezolute).

TypeBroad incumbent
Description

Established rare disease biopharma with commercial products across multiple ultra-rare metabolic and genetic conditions. Comparable orphan drug commercial model and regulatory strategy make BioMarin a benchmark for ersodetug's commercial trajectory.

TypeBroad incumbent
Description

Specialty pharma division focused on rare endocrine and metabolic disorders with established commercial presence. Overlap in rare metabolic disease focus and pediatric endocrinology customer base make Recordati a relevant broader incumbent peer.

TypeEmerging player
Description

Clinical-stage biotech developing peptide therapeutics for metabolic and rare diseases including congenital hyperinsulinism. Direct overlap in HI therapeutic development creates meaningful competitive and strategic comparability.

TypeEmerging player
Description

Rare disease biopharma with approved therapies in kidney and metabolic disorders. Similar clinical-to-commercial transition profile and rare disease commercial infrastructure provide a relevant comparable for Rezolute's commercialization planning.

TypeEmerging player
Description

Rare endocrine disease biopharma with approved pediatric endocrinology products (Skytrofa, Yorvipath). Comparable focus on rare endocrine/metabolic conditions and pediatric endocrinology prescriber base make Ascendis a relevant peer for commercial benchmarking.

TypeEmerging player
Description

Clinical-stage rare disease biopharma developing therapies for neurodegenerative and metabolic conditions. Similar clinical-stage profile and small-cap public company structure make Amylyx a useful operational and financial comparable.

TypeOthers
Description

Metabolic disease biopharma focused on NASH/MASH with approved resmetirone therapy. While not directly competitive, comparable public biopharma status and metabolic disease expertise make Madrigal a useful broader metabolic disease comparable for investor sentiment and valuation reference.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds19 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors19 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Rezolute

Rare Disease Biopharmaceuticalsrezolutebio.com

Rezolute is a clinical-stage biopharmaceutical company developing ersodetug, a fully human monoclonal antibody for hyperinsulinism, targeting rare pediatric congenital and adult tumor patient populations suffering severe hypoglycemia.

What Rezolute does

Rezolute (NASDAQ: RZLT) is a clinical-stage biopharmaceutical company developing ersodetug (RZ358), a fully human monoclonal antibody that binds allosterically to the insulin receptor in liver, fat, and muscle tissue to modulate insulin signaling. The company targets two forms of hyperinsulinism (HI): congenital hyperinsulinism (CHI), a rare pediatric genetic disorder affecting approximately 1 in 22,000 births worldwide, and tumor hyperinsulinism driven by insulinomas or non-islet cell tumors in adults. Two Phase 3 registrational trials are in progress: the sunRIZE study in CHI and the upLIFT study in tumor HI. The company holds multiple regulatory designations including FDA Orphan Drug, FDA Pediatric Rare Disease, EU Orphan Drug, EMA PRIME, UK ILAP Innovation Passport, and is engaging with FDA under Breakthrough Therapy framework following the December 2025 sunRIZE readout. Ersodetug's mechanism of action — acting downstream of the pancreas — provides potential pan-etiology efficacy across genetic, acquired, and tumor-driven forms of HI.

Rezolute's revenue model is contingent pharmaceutical drug sales targeting rare disease populations once regulatory approval is secured; the company is currently pre-revenue. Commercial infrastructure buildout is underway through a Chief Commercial Officer with prior ultra-rare disease launch experience (Crysvita at Ultragenyx), a Chief Regulatory Officer with 13 years at Genzyme, and a dedicated VP of Medical & Patient Affairs. Go-to-market positioning targets specialized endocrinology treatment centers and key opinion leaders, supplemented by an Expanded Access Program and The Rezolution patient community platform in collaboration with international advocacy organizations including Congenital Hyperinsulinism International.

The business carries a single-asset, binary-clinical-event risk profile. The December 2025 sunRIZE Phase 3 primary endpoint failure caused an 85–90% stock decline; the FDA subsequently declined to require a new controlled trial and encouraged broader data submission. The June 2026 positive upLIFT interim data and Guggenheim analyst modeling of approximately $850M in peak U.S. sales support a partial recovery narrative. Capital base stood at $120.3M cash and investments as of March 31, 2026, against a market capitalization of approximately $418M in June 2026, with the company's headquarters in Redwood City, California and additional offices in Bend, Oregon and New York.

Rezolute firmographics

Firmographics
Name
Rezolute
Legal name
Rezolute, Inc.
Website
https://rezolutebio.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
51–100 employees
Short description
Rezolute is a clinical-stage biopharmaceutical company developing ersodetug, a fully human monoclonal antibody for hyperinsulinism, targeting rare pediatric congenital and adult tumor patient populations suffering severe hypoglycemia.
Ownership category
akta.pro rank

Where Rezolute is headquartered

Location

Headquarters

HQ city
Redwood City
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Rezolute business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Drug Sales: Pre-revenue biopharmaceutical company developing er sodetug for treatment of congenital and tumor hyperinsulinism. Once approved, the company expects to generate revenue through pharmaceutical product sales targeting rare disease populations.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Rezolute product offering

Product offering

Core offering

Rezolute is developing ersodetug (RZ358), a fully human monoclonal antibody designed to treat all forms of hyperinsulinism (HI) by binding allosterically to the insulin receptor at liver, fat and muscle tissues to modulate insulin signaling and maintain glucose in a normalized range. The drug is being evaluated in two Phase 3 registrational trials: sunRIZE for congenital HI and upLIFT for tumor HI. The company also operates an Expanded Access Program (compassionate use) for patients with severe hypoglycemia and no alternative treatments.

Product overview

Rezolute is a biopharmaceutical company developing novel therapies for rare diseases, specifically focused on hypoglycemia caused by hyperinsulinism. The company's lead product is ersodetug (RZ358), a fully human monoclonal antibody that acts downstream from the pancreas to modulate insulin receptor signaling and maintain glucose levels. The development pipeline includes two Phase 3 registrational programs: the sunRIZE study for congenital hyperinsulinism and the upLIFT study for tumor hyperinsulinism. The company also operates an Expanded Access Program for compassionate use and supports patient communities through The Rezolution initiative. Currently, no product has received regulatory approval.

Differentiator

Problem solved

Functional benefit

Brands

  • The Rezolution: Patient advocacy and community initiative providing updates on therapy innovations, community events, and educational support for the hyperinsulinism community.

Products and services

  • Ersodetug (RZ358) Ersodetug (RZ358) is Rezolute's lead investigational product, a fully human monoclonal antibody designed to treat all forms of hyperinsulinism (HI). It binds allosterically to the insulin receptor at target tissues in the liver, fat and muscle to modulate the binding and signaling effects of insulin to help maintain glucose values in a normalized range, acting downstream of the pancreas for potential universal effectiveness. Currently in two Phase 3 registrational trials (sunRIZE for congenital HI and upLIFT for tumor HI).

Quantifiable outcome

  • 75% of tumor HI patients achieved complete discontinuation of IV dextrose/TPN support in Expanded Access Program
  • +2 more outcomes

Companies that use Rezolute

Customer profile

Segments2 records

Ideal customer profiles1 record

Rezolute technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Rezolute partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor and core.

  • NervGen PharmaminorOthersFormer Rezolute executive Keith Vendola joined NervGen Pharma as CFO, indicating personnel exchange between the companies but no active business partnership.
  • Congenital Hyperinsulinism International (CHI)coreStrategic or Co-development PartnerPatient advocacy organization founded by caregivers and patients impacted by HI. Rezolute's VP Medical & Patient Affairs previously served 7 years as Board President of CHI, helping launch the HI Global Registry and CHI Centers of Excellence program.
  • Patient Advocacy OrganizationscoreStrategic or Co-development PartnerRezolute collaborates with multiple patient advocacy organizations including hiperinsulinismo congenito, hyperinsulinismus.de (Germany), Children's HI Charity (UK), Insulinoma.co.uk, and Neuroendocrine Cancer Foundation. These organizations provide education, research, clinical care, and support to affected communities.

Scale indicators7 records

Recent moves6 records

Expansion highlights7 records

Rezolute competitors and assessment

Company assessment

Direct peers

  • Crinetics Pharmaceuticals: Clinical-stage biopharma developing therapies for rare endocrine diseases including acromegaly and congenital hyperinsulinism (paltusotine). Similar rare metabolic focus, comparable development stage, and overlapping target patient populations make Crinetics the most direct comparable.
  • Soleno Therapeutics: Rare disease biopharma focused on Prader-Willi syndrome and related metabolic disorders. Similar clinical-stage profile, ultra-rare disease commercial model, and comparable market capitalization make Soleno a closely matched peer.

Broad incumbents

  • Ultragenyx Pharmaceutical: Established commercial-stage rare disease company with multiple ultra-rare product launches including Crysvita for X-linked hypophosphatemia. Comparable ultra-rare disease commercial infrastructure and shared leadership bench (multiple ex-Ultragenyx executives at Rezolute).
  • BioMarin Pharmaceutical: Established rare disease biopharma with commercial products across multiple ultra-rare metabolic and genetic conditions. Comparable orphan drug commercial model and regulatory strategy make BioMarin a benchmark for ersodetug's commercial trajectory.
  • Recordati Rare Diseases: Specialty pharma division focused on rare endocrine and metabolic disorders with established commercial presence. Overlap in rare metabolic disease focus and pediatric endocrinology customer base make Recordati a relevant broader incumbent peer.

Emerging players

  • Zealand Pharma: Clinical-stage biotech developing peptide therapeutics for metabolic and rare diseases including congenital hyperinsulinism. Direct overlap in HI therapeutic development creates meaningful competitive and strategic comparability.
  • Travere Therapeutics: Rare disease biopharma with approved therapies in kidney and metabolic disorders. Similar clinical-to-commercial transition profile and rare disease commercial infrastructure provide a relevant comparable for Rezolute's commercialization planning.
  • Ascendis Pharma: Rare endocrine disease biopharma with approved pediatric endocrinology products (Skytrofa, Yorvipath). Comparable focus on rare endocrine/metabolic conditions and pediatric endocrinology prescriber base make Ascendis a relevant peer for commercial benchmarking.
  • Amylyx Pharmaceuticals: Clinical-stage rare disease biopharma developing therapies for neurodegenerative and metabolic conditions. Similar clinical-stage profile and small-cap public company structure make Amylyx a useful operational and financial comparable.

Others

  • Madrigal Pharmaceuticals: Metabolic disease biopharma focused on NASH/MASH with approved resmetirone therapy. While not directly competitive, comparable public biopharma status and metabolic disease expertise make Madrigal a useful broader metabolic disease comparable for investor sentiment and valuation reference.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

Rezolute social profiles

Digital presence

Rezolute compliance and trust

Trust signal

Compliance5 records

Rezolute financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Rezolute leadership team

Management profile

Number of profiles

Profiles8 records

Rezolute funding detail

Funding detail

Funding overview

Funding rounds19 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Rezolute M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rezolute

What does Rezolute do?

Rezolute is developing ersodetug (RZ358), a fully human monoclonal antibody designed to treat all forms of hyperinsulinism (HI) by binding allosterically to the insulin receptor at liver, fat and muscle tissues to modulate insulin signaling and maintain glucose in a normalized range. The drug is being evaluated in two Phase 3 registrational trials: sunRIZE for congenital HI and upLIFT for tumor HI. The company also operates an Expanded Access Program (compassionate use) for patients with severe hypoglycemia and no alternative treatments.

Is Rezolute a public or private company?

Rezolute is a public company. It is classified as public and is currently operating.

When was Rezolute founded?

Rezolute was founded in 2017. It employs 51 to 100 people.

Where is Rezolute based?

Rezolute is headquartered in Redwood City, United States, in the North America region.

How does Rezolute make money?

One revenue line is on record: pharmaceutical Drug Sales.

Who are Rezolute's main competitors?

Direct peers on record are Crinetics Pharmaceuticals and Soleno Therapeutics. Broad incumbents are Ultragenyx Pharmaceutical, BioMarin Pharmaceutical and Recordati Rare Diseases. Emerging players are Zealand Pharma, Travere Therapeutics, Ascendis Pharma and Amylyx Pharmaceuticals. Madrigal Pharmaceuticals is listed as an others.

Does Rezolute have an API?

No public API is recorded for Rezolute.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewWedbush maintains Rezolute at Outperform, raises price target to $10 from $6Wedbush maintained Rezolute at Outperform and raised its price target to $10 from $6, a 66.7% increase. The target implies an upside of 179.3% from the Nov 16 close of $3.58.TradingViewRezolute Prices $100 Million Stock and Warrant Offering, Expecting $93.5 Million NetRezolute entered an underwriting agreement for a public offering of 22,040,976 common shares at $3.87 per share and pre-funded warrants to purchase up to 3,800,000 shares at $3.869 each. The company expects net proceeds of approximately $93.5 million, which it will use to prepare for ersodetug commercialization and for working capital and general corporate purposes.YahooRezolute Raises $100 Million, Advances Ersodetug Toward CommercializationRezolute Inc. met the primary efficacy endpoint in its Phase 3 upLIFT study of ersodetug for tumor hyperinsulinism, with 13 of 16 participants meeting the responder threshold. The company priced an underwritten offering of 22,040,976 shares at $3.87 each, expecting roughly $100 million in gross proceeds to fund commercialization preparations.BenzingaRezolute Raises $100 Million, Advances Ersodetug Toward Commercialization - Rezolute (NASDAQ:RZLT)Rezolute Inc. met the primary efficacy endpoint in its Phase 3 upLIFT study of ersodetug, with 13 of 16 participants reducing glucose infusion by at least 50%. The company priced an underwritten offering of 22,040,976 shares at $3.87, expecting roughly $100 million in gross proceeds to fund commercialization.Seeking AlphaRezolute releases interim phase 3 results of ersodetug in tumor hyperinsulinismRezolute reported interim phase 3 data from its upLIFT study of ersodetug in tumor hyperinsulinism, where 13 of 16 enrolled patients achieved at least a 50% reduction in glucose infusion rate. Twelve of those 13 patients discontinued IV glucose use, and full results are expected by mid-December.TradingViewRezolute releases interim phase 3 results of ersodetug in tumor hyperinsulinismRezolute reported interim phase 3 results of ersodetug in tumor hyperinsulinism, where 13 of 16 enrolled patients achieved at least a 50% reduction in glucose infusion rate. Twelve of the 13 patients discontinued IV glucose use, and full results are expected by mid-December.MarketWatchRezolute Shares Climb on Positive Results from Late-Stage Study of Tumor Hyperinsulinism TreatmentRezolute shares rose 12% to $4.36 after its tumor hyperinsulinism treatment met the primary efficacy endpoint in a late-stage study. The company plans to advance both congenital and tumor hyperinsulinism into the approval process next year, with FDA discussions expected in the first quarter of 2027.Dealroom.coRezolute prices $100M stock offering led by Frazier Life Sciences | Dealroom NewsRezolute priced a $100M stock offering led by Frazier Life Sciences, with Morgan Stanley and Guggenheim as book-runners. The financing closes around November 16, 2026, and coincides with its Phase 3 upLIFT study meeting its primary efficacy endpoint. Proceeds will fund commercialization preparation for ersodetug, with a BLA submission targeted for mid-2027.TradingViewRezolute Reports Positive Phase 3 upLIFT Results, 13 of 16 Meet Response CriterionRezolute reported positive Phase 3 upLIFT results for ersodetug in tumor hyperinsulinism, with 13 of 16 participants meeting the primary endpoint of at least 50% glucose infusion rate reduction. The endpoint required 9 responders for statistical significance, and final analysis is pending. Topline results and additional details are expected by mid-December 2026.TradingViewRezolute prices $100M public offering of common stock and pre-funded warrantsRezolute priced an underwritten offering of 22.04 million common shares at $3.87 each, alongside 3.8 million pre-funded warrants, expected to raise about $100 million. The offering is scheduled to close around November 16, 2026, with proceeds used for working capital and general corporate purposes. Shares rose 6% in premarket trading.